Stifel raised the firm’s price target on HLS Therapeutics (HLTRF) to C$4.75 from C$4 and keeps a Hold rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential